tradingkey.logo


tradingkey.logo


AIM ImmunoTech Inc

AIM
0.557USD
-0.134-19.38%
終倀 03/30, 16:00ET15分遅れの株䟡
143.42K時䟡総額
損倱額盎近12ヶ月PER


AIM ImmunoTech Inc

0.557
-0.134-19.38%

詳现情報 AIM ImmunoTech Inc 䌁業名

AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.

AIM ImmunoTech Incの䌁業情報


䌁業コヌドAIM
䌚瀟名AIM ImmunoTech Inc
䞊堎日Jul 12, 1996
最高経営責任者「CEO」Equels (Thomas K)
埓業員数21
蚌刞皮類Ordinary Share
決算期末Jul 12
本瀟所圚地2117 Sw Highway 484
郜垂OCALA
蚌刞取匕所NASDAQ OMX – NASDAQ Basic Amex
囜United States of America
郵䟿番号32801
電話番号13524487797
りェブサむトhttps://aimimmuno.com/
䌁業コヌドAIM
䞊堎日Jul 12, 1996
最高経営責任者「CEO」Equels (Thomas K)

AIM ImmunoTech Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
63.91K
+39.12%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
25.64K
+97.50%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
-0.06%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
-0.03%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Ted D. Kellner
Mr. Ted D. Kellner
Independent Director
Independent Director
--
--
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
63.91K
+39.12%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
25.64K
+97.50%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
-0.06%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
-0.03%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--

収益内蚳

䌚瀟から関連デヌタがただ開瀺されおいたせん。
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Thu, Feb 19
曎新時刻: Thu, Feb 19
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
DRW Securities, LLC
1.65%
Equels (Thomas K)
1.51%
Kellner (Theodore D)
0.88%
Chemerow (David I)
0.61%
The Vanguard Group, Inc.
0.42%
他の
94.93%
株䞻統蚈
株䞻統蚈
比率
DRW Securities, LLC
1.65%
Equels (Thomas K)
1.51%
Kellner (Theodore D)
0.88%
Chemerow (David I)
0.61%
The Vanguard Group, Inc.
0.42%
他の
94.93%
皮類
株䞻統蚈
比率
Individual Investor
3.79%
Investment Advisor
2.10%
Investment Advisor/Hedge Fund
0.41%
他の
93.70%

機関投資家保有株


曎新時刻: Mon, Dec 8
曎新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q4
56
107.25K
2.64%
--
2025Q3
59
107.25K
2.79%
+95.13K
2025Q2
58
12.12K
12.55%
-36.20K
2025Q1
67
48.31K
13.00%
-45.65K
2024Q4
64
46.48K
14.87%
-43.65K
2024Q3
61
90.13K
15.18%
+5.69K
2024Q2
61
84.44K
8.12%
+43.50K
2024Q1
64
40.95K
9.51%
-6.49K
2023Q4
65
41.55K
9.71%
-1.72K
2023Q3
69
43.37K
10.32%
-1.62K
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
DRW Securities, LLC
43.29K
1.52%
+43.29K
--
Sep 30, 2025
Equels (Thomas K)
38.87K
1.36%
-15.00
-0.04%
Oct 24, 2025
Kellner (Theodore D)
37.20K
1.3%
+17.51K
+88.91%
Oct 24, 2025
Chemerow (David I)
641.00
0.02%
-1.00
-0.16%
Oct 24, 2025
The Vanguard Group, Inc.
17.50K
0.61%
+17.50K
--
Sep 30, 2025
Geode Capital Management, L.L.C.
16.19K
0.57%
+16.19K
--
Sep 30, 2025
Deutsch (Todd A)
17.16K
0.6%
--
--
Dec 19, 2024
Mitchell (William M)
5.22K
0.18%
-4.00
-0.08%
Oct 24, 2025
Rodino (Peter W III)
4.01K
0.14%
-7.00
-0.17%
Oct 24, 2025
Appelrouth (Stewart L.)
3.89K
0.14%
+670.00
+20.82%
Dec 31, 2024
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
比率0%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
配圓萜ち日
皮類
比率
Mar 03, 2025
Merger
100→1
日付
配圓萜ち日
皮類
比率
Mar 03, 2025
Merger
100→1
KeyAI
î™